Huntington's Disease

Aetna considers a range of imaging and molecular tests for Huntington’s disease experimental/investigational and not covered, including putaminal MRS (myo‑inositol and N‑acetylaspartate) for diagnosis; SERCA2 and VEGF mRNA biomarkers for monitoring; PET and functional neuroimaging (e.g., MRI) for progression/predicting pre‑manifest disease; and biomarkers such as basal ganglia iron, microRNAs, neurofilament light chain, salivary total huntingtin, tau, and blood transcriptomics. The key requirement for coverage is evidence of effectiveness, which Aetna states has not been established for these interventions.

"None explicitly stated. This Clinical Policy Bulletin addresses selected interventions for Huntington's disease and identifies numerous interventions and tests that Aetna considers experimental and..."

Sign up to see full coverage criteria, indications, and limitations.